drug · unknown
imetelstat sodium
Marketedupdated 3mo agoby $GERN GERON CORP🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Unknown drug with a maximum clinical stage of Approval (across all indications), with an approval for anemia and 5 investigational indications.
targets
Telomerase reverse transcriptase
all catalysts(2)
Trials studying imetelstat sodium
- phase1A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
- phase3Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- phase2Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 9, 2026
19 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Jun 16, 2039method-of-use (U-3956)US 12171778
- Jun 16, 2039method-of-use (U-3956)US 12171778
- Mar 15, 2033method-of-use (U-3956)US 12442000
- Mar 15, 2033method-of-use (U-3956)US 12442000
- Mar 15, 2033method-of-use (U-3956)US 9375485
- Mar 15, 2033method-of-use (U-3956)US 9375485
- Dec 27, 2026compositionUS 7494982128d
- Dec 27, 2026compositionUS 7494982128d
- Sep 9, 2026method-of-use (U-3956)US 938841519d
- Sep 9, 2026method-of-use (U-3956)US 938841519d
- Sep 9, 2026method-of-use (U-3956)US 938841619d
- Sep 9, 2026method-of-use (U-3956)US 938841619d
FDA exclusivities (2)
- Jun 6, 2031ODE-482Orphan Drug (7y)4.8y
- Jun 6, 2031ODE-482Orphan Drug (7y)4.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that